Company intelligence / Profile preview

Emmune

Cambridge, United Kingdom

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Emmune is developing eCD4-Ig, a synthetic antibody designed to neutralize all known strains of HIV by binding to CD4 and CCR5; AAV-delivered eCD4-Ig has shown durable protection against multiple SHIV challenges in rhesus macaques in preclinical studies, suggesting potential for long-acting treatment and prevention of HIV infection.[1][5]

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodyRecombinant proteinGene therapyAdeno-associated virus vectorBiologic
Industry: Biotech

Beyond the preview

Go deeper on Emmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emmune.

Explore the full profile